AbbVie’s oncology unit is projected to deliver nearly 4% sales growth in the fourth quarter, driven by recent approvals for Venclexta in combination therapies and the launch of Skyrizi’s oncology label expansion. These gains are expected to more than offset a double‐digit decline in Imbruvica revenue, which fell to $1.8 billion in the prior quarter. Management has guided to mid‐single‐digit oncology growth for the full year, signaling sustained momentum in this high‐margin business.

AbbVie has entered a three-year voluntary deal with the U.S. government that grants exemptions from existing tariffs and protection from future price controls. In return, the company will invest $100 billion in U.S. research, development and capital projects over the next decade, including manufacturing expansions across immunology and neuroscience facilities. The agreement also commits AbbVie to lower net prices for Medicaid patients through its TrumpRx program, covering treatments such as Humira, Synthroid and Alphagan.

AbbVie secured exclusive global rights (outside Greater China) to develop and commercialize RC148, a novel antibody–drug conjugate for advanced solid tumors, by paying RemeGen $650 million upfront and up to $4.95 billion in regulatory and sales milestones. The collaboration includes joint development governance and shared manufacturing responsibilities, positioning AbbVie to diversify its oncology pipeline and capture potential blockbuster sales if pivotal Phase III data meet primary endpoints in 2027.

The company agreed to acquire a Tempe, Arizona manufacturing site from West Pharmaceutical Services for $175 million, including 3.5 mL on-body injector technology and three biologics production lines. Closure is expected in mid-2026, with a planned addition of approximately 200 employees. AbbVie will invest an additional $50 million to modernize the plant, integrating it into its global network to support next-generation immunology and neuroscience therapies.